logo-loader

Algernon Pharmaceuticals gets warm reception from regulators for its planned Phase 2 coronavirus trial of ifenprodil

Published: 10:20 08 Apr 2020 EDT

Coronavirus graphic
Algernon is a drug repurposing company that investigates safe, already approved drugs for new disease applications

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) reported positive feedback from Health Canada on its planned Phase 2 study of its repurposed drug ifenprodil (NP-120) as a treatment for the coronavirus (COVID-19).

The company believes that ifenprodil could reduce both the severity and the duration of the coronavirus infection.

Based on the positive reception from Health Canada’s Office of Clinical Trials, Algernon has begun preparing a clinical trial application for a Phase 2 trial focused on severe coronavirus patients, which it expects to submit for approval within the next week.

READ: Algernon Pharmaceuticals finalizes protocol to launch Phase 2 trial of Ifenprodil for coronavirus patients

The company said it has received word that applications for coronavirus-related trials are being expedited.

“This was very good news for the company,” CEO Christopher Moreau said in a statement. “Receiving positive feedback from a major regulatory body is another significant step as we work to investigate our repurposed drug Ifenprodil as a possible therapeutic treatment for COVID-19.”

In addition to the trial in Canada, Algernon is working to support a planned investigator-led ifenprodil coronavirus trial in South Korea and a sponsored trial in Australia. The company has also filed a pre-Investigational New Drug application for a Phase 2 trial with the US Food and Drug Administration.

Algernon, based in Vancouver, is a drug repurposing company that investigates safe, already approved drugs for new disease applications. The company has filed new intellectual property rights around the world for Ifenprodil for the treatment of respiratory diseases and is working to develop a proprietary injectible, slow-release formulation.

Shares added over 6% in early Toronto deals to stand at C$0.25 each

---Updates for share price---

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

16 hours, 52 minutes ago